JP2016527230A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527230A5 JP2016527230A5 JP2016527006A JP2016527006A JP2016527230A5 JP 2016527230 A5 JP2016527230 A5 JP 2016527230A5 JP 2016527006 A JP2016527006 A JP 2016527006A JP 2016527006 A JP2016527006 A JP 2016527006A JP 2016527230 A5 JP2016527230 A5 JP 2016527230A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- tcr
- acid sequence
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 108091008874 T cell receptors Proteins 0.000 claims 21
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims 21
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 241000701806 Human papillomavirus Species 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 239000013604 expression vector Substances 0.000 claims 6
- 238000003259 recombinant expression Methods 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000006994 Precancerous Conditions Diseases 0.000 claims 2
- 210000002255 anal canal Anatomy 0.000 claims 2
- 210000000436 anus Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 210000003300 oropharynx Anatomy 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 210000003899 penis Anatomy 0.000 claims 2
- 210000003905 vulva Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019219105A JP6959970B2 (ja) | 2013-07-15 | 2019-12-03 | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 |
| JP2021166407A JP7223822B2 (ja) | 2013-07-15 | 2021-10-08 | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361846167P | 2013-07-15 | 2013-07-15 | |
| US61/846,167 | 2013-07-15 | ||
| PCT/US2014/046480 WO2015009606A1 (en) | 2013-07-15 | 2014-07-14 | Anti-human papillomavirus 16 e6 t cell receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019219105A Division JP6959970B2 (ja) | 2013-07-15 | 2019-12-03 | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527230A JP2016527230A (ja) | 2016-09-08 |
| JP2016527230A5 true JP2016527230A5 (cg-RX-API-DMAC10.html) | 2017-08-17 |
| JP6628719B2 JP6628719B2 (ja) | 2020-01-15 |
Family
ID=51298958
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016527006A Active JP6628719B2 (ja) | 2013-07-15 | 2014-07-14 | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 |
| JP2019219105A Active JP6959970B2 (ja) | 2013-07-15 | 2019-12-03 | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 |
| JP2021166407A Active JP7223822B2 (ja) | 2013-07-15 | 2021-10-08 | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019219105A Active JP6959970B2 (ja) | 2013-07-15 | 2019-12-03 | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 |
| JP2021166407A Active JP7223822B2 (ja) | 2013-07-15 | 2021-10-08 | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US9822162B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3022223B1 (cg-RX-API-DMAC10.html) |
| JP (3) | JP6628719B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN110511960B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2014290288B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2918216C (cg-RX-API-DMAC10.html) |
| ES (2) | ES2973064T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2015009606A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3149031T (pt) | 2014-05-29 | 2020-03-25 | Us Health | Receptores de células t anti-e7 do papilomavírus humano 16 |
| US9422547B1 (en) | 2015-06-09 | 2016-08-23 | Gigagen, Inc. | Recombinant fusion proteins and libraries from immune cell repertoires |
| EP3356396A1 (en) * | 2015-10-01 | 2018-08-08 | Ospedale San Raffaele S.r.l. | Tcr and uses thereof |
| CA2998270A1 (en) | 2015-10-01 | 2017-04-06 | Ospedale San Raffaele S.R.L. | Tcr and uses thereof |
| EP3156067A1 (en) * | 2015-10-16 | 2017-04-19 | Max-Delbrück-Centrum Für Molekulare Medizin | High avidity hpv t-cell receptors |
| WO2017139199A1 (en) | 2016-02-10 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible arginase |
| HRP20221375T1 (hr) * | 2016-03-16 | 2023-01-06 | Immatics Biotechnologies Gmbh | Transfecirane t-stanice i t-stanični receptori za upotrebu u imunoterapiji protiv raka |
| DK3448882T3 (da) | 2016-04-26 | 2022-02-21 | Us Health | Anti-kk-lc-1-t-cellereceptorer |
| DE102016115246C5 (de) * | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| ZA201900664B (en) | 2016-08-17 | 2021-09-29 | Paul Ehrlich Strasse 15 Tuebingen 72076 Germany | T cell receptors and immune therapy using the same |
| KR20190062505A (ko) * | 2016-10-03 | 2019-06-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | Hpv-특이적 결합 분자 |
| IL299348B2 (en) | 2017-06-28 | 2025-05-01 | Regeneron Pharma | Antigen-binding proteins against human papillomavirus and methods of using them |
| DE102017114737A1 (de) | 2017-06-30 | 2019-01-03 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| CA3070468A1 (en) | 2017-09-01 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Immunogenic peptides specific to bcma and taci antigens for treatment of cancer |
| US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| US12227554B2 (en) * | 2017-10-05 | 2025-02-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for selectively expanding cells expressing a TCR with a murine constant region |
| WO2019069125A1 (en) | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | CHIMERIC ANTIGEN RECEPTORS |
| JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
| ES3052818T3 (en) | 2018-02-09 | 2026-01-14 | Us Health | Tethered interleukin-15 and interleukin-21 |
| MA52003A (fr) | 2018-03-12 | 2021-01-20 | Sqz Biotechnologies Co | Procédés de traitement de maladies associées au hpv |
| CN112585276A (zh) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 产生表达重组受体的细胞的方法和相关组合物 |
| CN112585277A (zh) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 表达重组受体的t细胞、相关多核苷酸和方法 |
| CN112566698A (zh) | 2018-04-05 | 2021-03-26 | 朱诺治疗学股份有限公司 | T细胞受体和表达该t细胞受体的工程化细胞 |
| WO2019196088A1 (en) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
| CN112262212B (zh) | 2018-04-24 | 2024-07-12 | 美国卫生和人力服务部 | 使用羟基柠檬酸和/或其盐产生t细胞群体的方法 |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
| JP7289028B2 (ja) * | 2018-09-05 | 2023-06-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 複数の主要組織適合遺伝子複合体分子に制限したｎｙ－ｅｓｏ－１－特異的ｔ細胞受容体の組成物 |
| JP7504891B2 (ja) | 2018-09-11 | 2024-06-24 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞組成物のマススペクトロメトリー分析のための方法 |
| CN113727998A (zh) | 2018-11-30 | 2021-11-30 | 高山免疫科学股份有限公司 | Cd86变体免疫调节蛋白及其用途 |
| EP3941938A1 (en) | 2019-03-06 | 2022-01-26 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
| WO2020191365A1 (en) | 2019-03-21 | 2020-09-24 | Gigamune, Inc. | Engineered cells expressing anti-viral t cell receptors and methods of use thereof |
| CN113811329B (zh) | 2019-04-19 | 2025-10-14 | 天科雅生物科技有限公司 | 抗pd-1抗体和其用途 |
| CA3136737A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
| US20220213167A1 (en) * | 2019-05-03 | 2022-07-07 | Gigamune, Inc. | Engineered cells expressing anti-tumor t cell receptors and methods of use thereof |
| WO2021155518A1 (en) * | 2020-02-05 | 2021-08-12 | Tcrcure Biopharma Corp | Anti-hpv t cell receptors and engineered cells |
| EP4125949A4 (en) * | 2020-03-23 | 2024-05-22 | The Council of the Queensland Institute of Medical Research | COMPOSITIONS AND METHODS FOR TARGETING HPV-INFECTED CELLS |
| EP4171616A1 (en) | 2020-06-26 | 2023-05-03 | Juno Therapeutics GmbH | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| EP4243937A2 (en) | 2020-11-13 | 2023-09-20 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain |
| CN114539385A (zh) * | 2020-11-26 | 2022-05-27 | 香雪生命科学技术（广东）有限公司 | 一种识别hpv抗原的tcr |
| CN112480239B (zh) * | 2020-12-02 | 2022-06-07 | 中国科学院微生物研究所 | 人乳头瘤病毒特异性t细胞受体及其抗肿瘤用途 |
| CN114853878A (zh) * | 2021-02-03 | 2022-08-05 | 香雪生命科学技术（广东）有限公司 | 一种针对hpv的高亲和力tcr |
| EP4370541A1 (en) | 2021-07-14 | 2024-05-22 | 2seventy bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| WO2023036169A1 (en) * | 2021-09-07 | 2023-03-16 | Corregene Biotechnology Co., Ltd. | Antigen binding proteins and uses thereof |
| WO2023050063A1 (zh) * | 2021-09-28 | 2023-04-06 | 溧阳瑅赛生物医药有限公司 | 一种识别hla-a*02:01/e629-38的tcr及其应用 |
| US20250243260A1 (en) | 2022-03-07 | 2025-07-31 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses |
| WO2023196884A1 (en) | 2022-04-06 | 2023-10-12 | Juno Therapeutics, Inc. | Detection assay for human papillomavirus (hpv) type 16 (hpv-16) |
| AU2023248532A1 (en) | 2022-04-08 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Multipartite receptor and signaling complexes |
| CN115286690B (zh) * | 2022-05-10 | 2023-06-20 | 广州医科大学 | 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr |
| AU2025212850A1 (en) | 2024-01-26 | 2026-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1 |
| CN118108854B (zh) * | 2024-03-26 | 2024-07-19 | 广西福莱明生物制药有限公司 | 一种含有双特异性抗体的抗病毒组合物及其应用 |
| WO2025250587A1 (en) | 2024-05-29 | 2025-12-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Drug-regulatable, inducible cytokine expression |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IN165717B (cg-RX-API-DMAC10.html) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| JPH10509948A (ja) * | 1994-11-16 | 1998-09-29 | バクスター インターナショナル インコーポレイテッド | Ｔ細胞受容体ペプチドに対するヒト抗体およびそれらの調製方法 |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| US8185966B2 (en) * | 2005-07-25 | 2012-05-22 | Trinity Future-IN PVT, Ltd. | Electro-mechanical system for non-duplication of video files |
| US20090304657A1 (en) * | 2006-05-03 | 2009-12-10 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
| CA2674445C (en) * | 2007-01-12 | 2016-06-07 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Gp100-specific t cell receptors and related materials and methods of use |
| EP2468763B1 (en) | 2007-05-31 | 2014-06-18 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| GB0917090D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| US9345748B2 (en) * | 2010-09-21 | 2016-05-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-SSX-2 T cell receptors and related materials and methods of use |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
-
2014
- 2014-07-14 CN CN201910649441.7A patent/CN110511960B/zh active Active
- 2014-07-14 US US14/905,108 patent/US9822162B2/en active Active
- 2014-07-14 EP EP14748353.1A patent/EP3022223B1/en active Active
- 2014-07-14 JP JP2016527006A patent/JP6628719B2/ja active Active
- 2014-07-14 AU AU2014290288A patent/AU2014290288B2/en active Active
- 2014-07-14 EP EP19180239.6A patent/EP3572423B1/en active Active
- 2014-07-14 CN CN201480044286.1A patent/CN105452288B/zh active Active
- 2014-07-14 CA CA2918216A patent/CA2918216C/en active Active
- 2014-07-14 WO PCT/US2014/046480 patent/WO2015009606A1/en not_active Ceased
- 2014-07-14 ES ES19180239T patent/ES2973064T3/es active Active
- 2014-07-14 ES ES14748353T patent/ES2745472T3/es active Active
-
2017
- 2017-10-18 US US15/786,966 patent/US10329339B2/en active Active
-
2019
- 2019-05-10 US US16/408,939 patent/US10913785B2/en active Active
- 2019-12-03 JP JP2019219105A patent/JP6959970B2/ja active Active
-
2021
- 2021-01-06 US US17/142,486 patent/US11697676B2/en active Active
- 2021-10-08 JP JP2021166407A patent/JP7223822B2/ja active Active
-
2023
- 2023-05-25 US US18/323,493 patent/US12187779B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524372A5 (cg-RX-API-DMAC10.html) | ||
| JP2023159112A5 (cg-RX-API-DMAC10.html) | ||
| Crosbie et al. | Human papillomavirus and cervical cancer | |
| FI3688027T3 (fi) | Mutatoidun p53:n tunnistavia t-solureseptoreita | |
| HRP20200376T1 (hr) | Receptori t-stanica protiv ljudskog papiloma virusa 16e7 | |
| JP2014500002A5 (cg-RX-API-DMAC10.html) | ||
| JP2018530331A5 (cg-RX-API-DMAC10.html) | ||
| Al Moustafa et al. | Human papillomaviruses-related cancers: Presence and prevention strategies in the Middle East and North African Regions | |
| JP2014239695A5 (cg-RX-API-DMAC10.html) | ||
| JP2007506417A5 (cg-RX-API-DMAC10.html) | ||
| JP2014528714A5 (cg-RX-API-DMAC10.html) | ||
| Li et al. | Nanobody against the E7 oncoprotein of human papillomavirus 16 | |
| Iuliano et al. | Human Papillomavirus E6 and E7 oncoproteins affect the cell microenvironment by classical secretion and extracellular vesicles delivery of inflammatory mediators | |
| CN101186636A (zh) | 人乳头瘤病毒外壳蛋白l1短肽及其应用 | |
| Gurgel et al. | Prevalence of human papillomavirus variants and genetic diversity in the L1 gene and long control region of HPV16, HPV31, and HPV58 found in North‐East Brazil | |
| Vergara et al. | Detection and quantitation of human papillomavirus DNA in peripheral blood mononuclear cells from blood donors | |
| Dhanushkodi et al. | Mucosal CCL28 Chemokine Improves Protection against Genital Herpes through Mobilization of Antiviral Effector Memory CCR10+ CD44+ CD62L− CD8+ T Cells and Memory CCR10+ B220+ CD27+ B Cells into the Infected Vaginal Mucosa | |
| Mocarska et al. | Epidemiology and risk factors of the cervical squamous cell carcinoma | |
| Sharma et al. | Impact of HPV strains on molecular mechanisms of cervix cancer | |
| JP2017536821A5 (cg-RX-API-DMAC10.html) | ||
| Mahmoudi et al. | Prostate cancer and human papillomavirus infection: a recent literature review | |
| Arregui et al. | Oncogenic human papillomaviruses: high-risk human papillomaviruses: towards a better understanding of the mechanisms of viral transformation, latency and immune-escape | |
| Trimble | HPV Infection–Associated Cancers: Next-Generation Technology for Diagnosis and Treatment | |
| Dhanushkodi et al. | High Frequencies of Antiviral Effector Memory TEM Cells and Memory B Cells Mobilized into Herpes Infected Vaginal Mucosa Associated With Protection Against Genital Herpes | |
| Zheng et al. | Production of polyclonal antibody to the HPV58 E7 protein and its detection in cervical cancer |